Evidence map›Paper›PMID 26542942›Full record

ArticleMalaria journal2015

High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.

Vito Baraka, Deus S Ishengoma, Filbert Fransis, Daniel T R Minja, Rashid A Madebe, Deogratius Ngatunga, Jean-Pierre Van Geertruyden

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Vito BarakaNational Institute for Medical Research, Tanga Research Centre, P. O. Box 5004, Tanga, United Republic of Tanzania. vitobaraka@gmail.com.
Deus S IshengomaNational Institute for Medical Research, Tanga Research Centre, P. O. Box 5004, Tanga, United Republic of Tanzania. deusishe@yahoo.com.
Filbert FransisNational Institute for Medical Research, Tanga Research Centre, P. O. Box 5004, Tanga, United Republic of Tanzania. ffrancis8@gmail.com.
Daniel T R MinjaNational Institute for Medical Research, Tanga Research Centre, P. O. Box 5004, Tanga, United Republic of Tanzania. minjartd@gmail.com.
Rashid A MadebeNational Institute for Medical Research, Tanga Research Centre, P. O. Box 5004, Tanga, United Republic of Tanzania. ramadebe11@gmail.com.
Deogratius NgatungaTanzania Food and Drugs Authority, P: O. Box 77150, Dar es Salaam, United Republic of Tanzania. degrate79@gmail.com.
Jean-Pierre Van GeertruydenInternational Health Unit, Department of Epidemiology, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610, Wilrijk, Belgium. jean-pierre.vangeertruyden@uantwerpen.be.
National Institute for Medical Research · TZUniversity of Antwerp · BEEckernforde Tanga University · TZTanzania Food and Nutrition Center · TZ

Funding

Medical Research Council G0600718
6 · The paper itself

Abstract

backgroundTanzania abandoned sulfadoxine-pyrimethamine (SP) as the first-line treatment for uncomplicated malaria in 2006 due to high levels Plasmodium falciparum resistance. However, SP is still being used for intermittent preventive treatment during pregnancy (IPTp-SP). This study aimed to assess the pattern of P. falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations and associated haplotypes in areas with different malaria transmission intensities in mainland Tanzania, 6 years after withdrawal of SP as a first-line treatment regimen for uncomplicated malaria.

methodsA total of 264 samples were collected during cross-sectional surveys in three districts of Muheza, Muleba and Nachingwea in Tanga, Kagera and Lindi regions, respectively. Parasite genomic DNA was extracted from P. falciparum positive samples. The Pfdhfr, Pfdhps single nucleotide polymorphisms (SNPs) were amplified using nested polymerase chain reaction and detected by sequence specific oligonucleotide probe-enzyme linked immunosorbent assay (SSOP-ELISA).

resultsThe prevalence of the mutant Pfdhfr-Pfdhps haplotypes was heterogenous and transmission dependent. The triple Pfdhfr mutant haplotypes (CIRNI) were predominant in all sites with significantly higher frequencies at Muheza (93.3 %) compared to Muleba (75.0 %) and Nachingwea districts (70.6 %), (p < 0.001). Overall, the prevalence of the wild-type Pfdhps (SAKAA) haplotype was lowest at Muheza (1.3 %), (p = 0.002). Double Pfdhps haplotype SGEAA was significantly high at Muheza (27.2 %) and Muleba (20.8 %) while none (0 %) was detected at Nachingwea (p < 0.001). The prevalence of triple Pfdhps SGEGA haplotype was significantly higher at Muheza compared to Muleba and Nachingwea (p < 0.001). In contrast, Nachingwea and Muleba had significantly higher prevalence of another triple Pfdhps AGEAA haplotype (χ(2) = 39.9, p < 0.001). Conversely, Pfdhfr-Pfdhps as quintuple and sextuple haplotypes were predominant including the emergence of a septuple mutant haplotype CIRNI-AGEGA (n = 11) observed at Muheza and Muleba.

conclusionThese results ascertain the high prevalence and saturation of Pfdhfr and Pfdhps haplotypes conferring SP resistance in areas with changing malaria epidemiology; and this could undermine the use of IPTp-SP in improving pregnancy outcomes. In these settings where high level SP resistance is documented, additional control efforts are needed and evaluation of an alternative drug for IPTp is an urgent priority.

Indexed as

Drug ResistanceAntimalarialsBiomarkersCross-Sectional StudiesDihydropteroate SynthaseDrug CombinationsEnzyme-Linked Immunosorbent AssayHaplotypesMutationPlasmodium falciparumPolymerase Chain ReactionProtozoan ProteinsPyrimethamineSulfadoxineTanzaniaTetrahydrofolate DehydrogenaseAntimalarialsBiomarkersDihydropteroate SynthaseDrug Combinationsfanasil, pyrimethamine drug combinationProtozoan ProteinsPyrimethamineSulfadoxineTetrahydrofolate Dehydrogenase

Identifiers

PMID26542942
PMCPMC4635599
OpenAlexW2149086938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.